🇺🇸United States·March 03, 2026·daily

S&P 500 Technology Sector SEC Filings — March 03, 2026

Across 12 SEC 8-K filings in the USA S&P 500 Technology stream (though spanning utilities, biotech, finance, and consumer alongside core tech like CrowdStrike and IBM), dominant themes include capital raising via at-the-market (ATM) offerings (TXNM Energy $125M, Tharimmune/Canton $300M), mixed financial results with revenue growth in CrowdStrike (+23% YoY Q4 FY26 to $1.31B, ARR +24% to $5.25B) offset by NAV declines in Oxford Square Capital (-13% QoQ to $1.69/share) and persistent net losses in Immunome (-$212M FY25, improved 27% YoY), and forward-looking catalysts like partnerships (Adial $60M potential) and guidance raises (CrowdStrike FY27 ARR $6.47B-$6.52B). Period-over-period trends show selective strength in subscription margins (CrowdStrike +200bps YoY GAAP Q4) and cash runway extensions (Immunome to 2028 via $432M net raise), but dilution risks from ATMs and failed quorums (Adial). Exec changes signal transitions (Smucker COO separation, Community West COO retirement), while capital allocation leans toward distributions (Oxford monthly $0.035/share) and buybacks (CrowdStrike $51M). Overall neutral-to-mixed sentiment (8/10 filings neutral/mixed) implies portfolio caution in tech, favoring CrowdStrike outperformance amid sector growth but watching biotech/fintech volatility for alpha.

6 high priority6 medium12 total filings

🇺🇸United States·March 03, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 03, 2026

Across 10 SEC 8-K filings from NASDAQ-100 constituents on March 3, 2026, dominant themes include capital raising via at-the-market (ATM) offerings by TXNM Energy ($125M) and Canton Strategic Holdings/Tharimmune ($300M), signaling liquidity bolstering amid neutral sentiment; executive transitions at Intel (Chair retirement), J.M. Smucker (COO separation), and Community West Bancshares (COO retirement); and biotech advancements with Immunome's 27% YoY net loss improvement to $212.4M, cash runway to 2028, and Phase 3 success (84% risk reduction, HR=0.16), alongside Adial's mixed Europe partnership potential (~$60M value). Period-over-period trends are limited but highlight Immunome's R&D expenses up 37% YoY to $177.3M and collaboration revenue down 23% to $6.9M, contrasting sharply improved loss per share ($(2.43) vs. $(5.00)). No insider trading activity reported across filings, but TXNM's 2026 incentive plans tie bonuses to EPS thresholds (up to 230% salary) and LTIP to earnings growth/FFO metrics through 2028, aligning management. Portfolio-level patterns show dilution risks from ATMs (total ~$425M potential), offset by Immunome's strong pipeline catalysts and Adial's commercialization pathway, with neutral-to-mixed sentiment (6/10 neutral) implying stable but non-explosive near-term implications; investors should prioritize biotech catalysts over governance noise.

6 high priority4 medium10 total filings

🇺🇸United States·March 03, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 03, 2026

Across 79 SEC filings from DJ30-related and associated US blue-chips on March 3, 2026, dominant themes include robust M&A activity (e.g., Select Medical $3.9B takeover at 18-25% premium, Flowco $200M Valiant acquisition), mixed Q4/FY2025 earnings with average revenue growth of ~20% YoY in reporting firms (e.g., EVgo +75% Q4, Limbach +24.7% FY) offset by widespread margin compression averaging -150bps (e.g., Mayville EBITDA margin 7.6% to 4.7%, Limbach gross 27.8% to 26.2%). Capital allocation leans shareholder-friendly with buybacks (Limbach $50M, Civeo 10% authorization, Kontoor $25M) and dividends (Versant $0.375/share), alongside debt refinancings improving terms (Vertiv investment-grade upgrade, Adtalem lower margins). Forward guidance for 2026 shows cautious optimism with revenue growth projections of 5-15% in most (e.g., CrowdStrike ARR to $6.47-6.52B +24% implied), but flat/declining EBITDA in others (EVgo -$20M to $20M). Insider activity is minimal but neutral (e.g., Innventure tax withholdings), with no major sells signaling conviction. Portfolio-level trends flag healthcare/tech outperformance vs. cyclical softness in manufacturing/energy, with 12/79 filings highlighting spin-offs/divestitures (Honeywell Aerospace, Ziff Davis $1.2B Connectivity sale) as deleveraging catalysts. Overall, actionable alpha lies in M&A premiums and guidance beats amid tariff/inflation risks.

31 high priority48 medium79 total filings

🇺🇸United States·March 03, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 03, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream (broadly including retail, autos, and adjacent), sentiment is mixed-positive with 18 positive, 12 mixed, 10 neutral, and few negative, driven by robust M&A (e.g., Flowco $200M, Cal-Maine $130M, Ziff Davis $1.2B divestiture) and capital returns (Ross Stores $2.55B buyback +21%, MarketWise $0.45 total dividend), offsetting earnings pressures. Period-over-period trends show retail sales growth averaging +7% YoY in outperformers like Ross (+12%) and AutoZone (+8%) but declines in Target (-1.5%) and B&G Foods (-2.2%), with margin compression widespread (-137bps AutoZone, -260bps L.B. Foster). Capital allocation leans shareholder-friendly (dividend hikes, buybacks, debt refinancings lowering costs like HA Sustainable 8% to 7.125%), while forward guidance is cautious (Target ~2% sales growth, Ross 3-4% comps). Insider conviction absent in most but supported by 10b5-1 plans (Smart Sand) and board expansions. Key implications: tactical buys in strong retail comps amid M&A wave, watch margin trends and Q1 catalysts for portfolio rotation.

14 high priority36 medium50 total filings

🇺🇸United States·March 03, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 03, 2026

Across 17 SEC filings from the USA S&P 500 Healthcare stream (including biotech, pharma, providers, and tangential sectors), key themes include positive regulatory milestones and M&A approvals in biotech (e.g., FDA Priority Review, merger votes), mixed financial results with revenue growth in some (Prime Medicine +55% YoY) offset by widening losses (CalciMedica net loss +116% YoY), aggressive capital returns via buybacks (Roivant $1B new program, Civeo new 10% authorization), and leadership transitions (Cigna CEO retirement, Protagenic new President). Period-over-period trends show 3/5 reporting companies with YoY revenue growth (avg +29%) but 4/5 with wider net losses (avg +42%), highlighting R&D intensity in biotech; Australian operations boosted Civeo Q4 EBITDA +90% YoY. Critical developments like Roivant's $2.25B Moderna settlement and Ventyx's 96% merger approval signal liquidity boosts and strategic exits, while trial setbacks (CalciMedica) flag risks. Portfolio-level patterns reveal biotech conviction via capital allocation (buybacks up) amid cash runways into 2027, positioning sector for catalysts but vulnerable to clinical risks.

4 high priority13 medium17 total filings

🇺🇸United States·March 02, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 02, 2026

Across 34 diverse SEC filings labeled under S&P 500 Consumer Staples (though spanning energy, tech, biotech, REITs, media), overarching themes reveal mixed sentiment with robust revenue growth in 9/18 reporting companies averaging +18% YoY (e.g., MongoDB +27%, Helios +17% Q4), offset by declines in 6 averaging -4% YoY (Alamo -3%, Mobile Infra -4.3%) and margin compression in 7/15 cases by -130bps avg (Alamo -140bps Q4, Great Elm NAV -20% QoQ). Capital allocation shines with buybacks totaling >$430M (ADMA $200M, Proficient $15M, DiamondRock $37M past) and dividends hikes (Alamo +13.3%, Helios 116 qtrs), signaling management conviction amid $2.5B+ in M&A/debt moves (Paramount $81B, Kosmos $220M sale). Insider activity sparse but mixed at Coca-Cola Europacific (exec sales $1.4M offset by routine buys). Forward-looking data flags modest growth guidance in 6 firms (midpoints +4-7%) and catalysts like satellite launches (AST Q1 2026). Critical risks include Elevance Health CMS sanctions (Mar 31) and impairments (Kosmos $178M), while portfolio trends point to resilient cash flows (Helios record $127M FY) supporting returns. Implications: Bullish on capital return plays and growth outliers, bearish on reg/impaired names; sector shows defensive buyback trends despite macro pressures.

15 high priority19 medium34 total filings

🇺🇸United States·March 02, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 02, 2026

Across 71 SEC filings from the USA S&P 500 Industrials stream and related sectors, overarching themes include robust M&A activity (12+ completions like ITT's $4.8B SPX FLOW acquisition and bank mergers boosting assets 20-42% YoY), strong revenue growth in energy/industrials (e.g., Venture Global +177% YoY to $13.8B, Federal Signal +17% to $2.18B), but mixed profitability with 6/15 high-materiality reports showing EPS/net income declines (avg -50% YoY). Period-over-period trends reveal YoY revenue acceleration averaging +40% in growth outperformers (10 filings >50%), offset by margin compression in 7 cases (avg -150bps, e.g., Sturm Ruger gross profit -29%), alongside positive capital returns ($500M+ buybacks/dividends across 8 firms). Critical developments: Guidance cuts (Whirlpool EPS -14% to $6), raises (Xeris +30% to $375-390M), defense hires (L3Harris/Eaton CFOs), and Phase 3 catalysts (EyePoint/Rhythm PDUFA Mar 20). Portfolio-level patterns signal industrial consolidation via M&A (ITT/Federal Signal), resilient cash flows (Tidewater FCF $426M), but watch profitability volatility and delistings (Graphjet). Market implications favor M&A plays and growth industrials, with caution on consumer/manufacturing slowdowns.

37 high priority34 medium71 total filings

🇺🇸United States·March 02, 2026·daily

S&P 500 Energy Sector SEC Filings — March 02, 2026

Across the 7 filings in the USA S&P 500 Energy intelligence stream, key themes include proactive capital allocation with debt refinancings (Targa's $1.5B notes issuance, Peapack's $100M notes redemption), share repurchases (XOMA's $16M buyback reducing shares 5%), and M&A progress (Baker Hughes' Chart Industries merger financials filing), alongside governance resolutions (Dorchester's Nasdaq compliance fix) and mixed biotech updates (XOMA royalties ~$49-50M FY2025 prelim, Bioxytran trial). Period-over-period insights are limited but highlight XOMA's robust FY2025 royalty receipts ($22.5M Wet AMD/DME/RVO YTD, up via new 24 assets added) vs no broad YoY declines noted; energy firms show balance sheet strengthening without margin compression signals. Critical developments imply sector resilience with Targa's positive sentiment (9/10) signaling growth funding, Baker's neutral M&A advancement (7/10 materiality), and Dorchester's compliance closure reducing overhangs. Portfolio-level patterns reveal 3/7 filings with capital returns/raises (avg materiality 8.7/10), favoring bullish positioning amid stable operations. No insider selling patterns detected; forward-looking catalysts cluster in XOMA's 2026 pipeline (e.g., Seralutinib data, ersodetug approvals). Market implications: Energy players like Targa/Baker prioritize capex/deals, actionable for long positions pre-catalysts.

2 high priority5 medium7 total filings

🇺🇸United States·March 02, 2026·daily

S&P 500 Financials Sector SEC Filings — March 02, 2026

Across 304 SEC filings from S&P 500 Financials and broader US equities (though heavily skewed to biotech, energy, and industrials), overarching themes include robust revenue growth averaging +25% YoY in high-materiality reporters (e.g., Venture Global +177%, Astrana Health +56%), but widespread margin compression (-100 to -200 bps average in 12/20 mixed sentiment filers like Sturm Ruger, Plug Power) and mixed profitability amid rising OpEx/R&D. Financials show shareholder-friendly capital allocation with dividend hikes (Amex +15.9%, PROG +7.7%) and buybacks (Klaviyo $500M, ADMA $200M), while biotech dominates forward-looking catalysts (20+ Phase 2/3 readouts H1-H2 2026). M&A activity surges (30+ deals, e.g., Warner Bros $81B, Malibu Boats accretive), insider conviction mixed (Coca-Cola exec sales $1.4M but small buys), and guidance largely raised (e.g., Lumexa +3-8%, Xeris +30%). Portfolio-level trends: 65/304 positive sentiment, revenue YoY up in 180/304, but net losses in 40% due to impairments/restructurings; net leverage improving in 15 BDCs/REITs (avg 1.5-3x). Implications: Bullish for growth sectors with catalysts, cautious on margins/expenses; actionable now on dividend payers and H1 biotech events.

125 high priority179 medium304 total filings

🇺🇸United States·March 02, 2026·daily

S&P 500 Technology Sector SEC Filings — March 02, 2026

Across the 8 S&P 500 Technology stream filings dated around March 2, 2026, dominant themes include aggressive capital returns via share repurchases in software firms (Klaviyo $500M program + $100M ASR imminent; Synopsys $250M ASR), signaling strong management conviction amid neutral governance changes (Datadog board expansion, Broadcom director retirement). Intuitive Surgical's completion of a key acquisition enhances its distribution footprint, while Murphy USA (outlier retail) reports mixed 2025 results with EBITDA up slightly YoY to $1.02B from $1.01B but fuel volumes down 3.0% YoY and OpEx up 5.8% to $763M, issuing cautious 2026 guidance for continued fuel declines (-3.0% to -1.0%). ACNB's note redemption and C2 Blockchain's micro-equity raise highlight debt management and dilution risks in non-core names. Portfolio-level trends show 2/8 companies pursuing major buybacks (positive for EPS accretion), limited YoY growth visibility except Murphy's flat contributions, and forward catalysts like ASR settlements and redemptions creating near-term volatility. Overall sentiment leans positive from capital allocation (3 positive filings) but mixed ops signal sector resilience with pockets of pressure; investors should prioritize buyback initiators for alpha amid low M&A disclosure.

2 high priority6 medium8 total filings

🇺🇸United States·March 02, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 02, 2026

Across these 6 NASDAQ-100 filings dated March 2, 2026, overarching themes include strategic expansions in AI/security (AITX), resilient retail operations amid headwinds (Murphy USA), board governance refreshes (CCC, Broadcom), biotech capital access (Intellia), and M&A completion in robotics (Intuitive Surgical), with 5/6 filings carrying positive sentiment versus one mixed. Key period-over-period trends highlight Murphy USA's Adjusted EBITDA up slightly YoY to $1.02B from $1.01B despite -3.0% same-store fuel volume decline and +5.8% store OpEx to $763M, marking an outlier in detailed financial disclosures while others focus on non-financial catalysts. Critical developments like Intellia's 38% ATM capacity expansion to $1.035B and Intuitive's acquisition closure signal funding flexibility and market penetration, but Murphy's FY2026 guidance flags ongoing -3.0% to -1.0% fuel volume declines. Portfolio-level patterns show tech/AI firms pursuing partnerships and audits for credibility (AITX SOC 2), contrasting retail's flat fuel contribution amid competition from 600+ new stores since 2020. Overall, bullish operational momentum in 4/6 companies supports near-term upside, tempered by retail sector pressures.

3 high priority3 medium6 total filings

🇺🇸United States·March 02, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 02, 2026

Across 92 SEC filings from Dow Jones 30-related and blue-chip streams dated March 2, 2026, dominant themes include robust revenue growth in energy/LNG (e.g., Venture Global +177% YoY to $13.8B) and biotech (e.g., Xeris +43.7% FY revenue), offset by mixed results in cruises and E&P with margin pressures; banking sector shows aggressive M&A consolidation (7+ deals adding billions in assets). Period-over-period trends reveal 18/92 companies with >30% YoY revenue growth (avg +65%), but 12/92 reported net losses or impairments amid higher expenses; capital allocation leans bullish with 9 dividend hikes (e.g., Amex +16%) and 5 buyback expansions (e.g., Klaviyo $500M). Insider activity is sparse but mixed (Coke PDMR sales $1.4M countered by buys), while forward guidance is raised in 15 cases (e.g., Dave 25-28% revenue growth). M&A activity surges (12 deals, e.g., Warner Bros $31/share cash merger), signaling portfolio optimization, but regulatory risks loom (Elevance CMS sanctions). Overall, bullish momentum in healthcare/tech/energy supports DJ30 outperformance, with banking M&A as a key alpha driver amid 5.3x avg net leverage stability.

45 high priority47 medium92 total filings

🇺🇸United States·March 02, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 02, 2026

Across 51 filings in the S&P 500 Consumer Discretionary intelligence stream (with heavy financial services overlap), Q4/FY2025 results show mixed performance: 6/10 reporting companies experienced YoY revenue declines averaging -12% (e.g., Core Scientific -16%, Crawford -11%, Mobile Infra -4.3%), driven by weather disruptions, lower claims/volumes, and transients, while outliers like Life360 (+32% revenue) and Riot Platforms (+72%) posted strong growth. Bank/financial M&A dominated with 8 completions (e.g., HBT Financial, Farmers National, First Mid) boosting assets 30-42% on average, signaling consolidation. Capital allocation remains shareholder-friendly: 5 buyback/dividend hikes (Proficient $15M repurchase, WhiteHorse insiders bought $8M shares), but insider sales in CCE (execs sold $1.4M) flag caution. Forward guidance stable (Mobile Infra +4-7% 2026 rev/NOI growth), with power expansions (Core Scientific +730MW) and venue reopenings as catalysts. Portfolio trend: margin volatility (gross margins expanded in Life360 +3pp, compressed elsewhere), liquidity strong ($1.9B Riot, $533M Core), but restatements (Core Scientific) and debt rises (TPG 2.14x to 3.0x) add risks. Implications: Favor M&A beneficiaries and growth outliers for upside, monitor weather-sensitive ops.

22 high priority29 medium51 total filings

🇺🇸United States·March 02, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 02, 2026

Across 35 filings in the USA S&P 500 Healthcare stream (with broader market exposure including biotechs, insurers, banks, and others), overarching themes include robust biotech pipeline advancements and financings (e.g., NewAmsterdam's Phase 3 successes, Zymeworks' $250M royalty deal), active M&A/integration (9 deals like HBT Financial, Rallybio, Intuitive Surgical), steady capital returns via buybacks/dividends (Tidewater $500M auth, Stewart $0.525/share), but mixed financials with 6/12 reporting entities showing YoY revenue declines (avg -15%, e.g., Core Scientific -16%, Zymeworks Q4 -92%). Healthcare-specific trends highlight positive clinical catalysts (NewAmsterdam 35-40% LDL-C reduction, Tyra data readouts 2026) offset by insurer risks (Elevance CMS sanctions threat), while period comparisons reveal biotech net losses widening (Tyra FY +39% to $119.9M) amid R&D ramps (+27-29% YoY). Insider activity mixed with sales at Coca-Cola Europacific ($1.41M total) but routine buys; capital allocation favors deleveraging (Peapack $100M redemption) and repurchases. Portfolio implications: overweight biotechs with 2026 catalysts, monitor insurer regulatory overhangs for near-term volatility.

14 high priority21 medium35 total filings